The Otsuka Pharmaceutical and Click Therapeutics mobile app Rejoyn received FDA clearance for use as an adjunct to medication in the treatment of major depressive disorder. But Otsuka must overcome hurdles facing digital therapeutics products, which have yet to gain traction among payers.
Related Articles
Understanding the Use and Risks of Gynecology Laparoscopy
Gynecology Laparoscopy is a minimally invasive surgical procedure used by doctors to...
Medicare’s Hidden Information Hurts People & Policy
By MICHAEL MILLENSON Open enrollment season for Medicare, which began Oct. 15...
How One Massachusetts Maternal Mental Health Program Scaled Across the Country
During a recent panel, experts discussed the Massachusetts Child Psychiatry Access Program...
DTC Marketing for Medical Device and Other Healthcare Organizations
Could direct-to-consumer (DTC) healthcare marketing be the key to building deeper patient...
Leave a comment